168 related articles for article (PubMed ID: 16793840)
21. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
22. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
[TBL] [Abstract][Full Text] [Related]
23. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
[TBL] [Abstract][Full Text] [Related]
24. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
Buch MH; Bingham SJ; Bryer D; Emery P
Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
[TBL] [Abstract][Full Text] [Related]
25. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
26. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
Nissinen R; Leirisalo-Repo M; Peltomaa R; Palosuo T; Vaarala O
Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
[TBL] [Abstract][Full Text] [Related]
27. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
28. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
29. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
30. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
31. Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
Ortea I; Roschitzki B; López-Rodríguez R; Tomero EG; Ovalles JG; López-Longo J; de la Torre I; González-Alvaro I; Gómez-Reino JJ; González A
PLoS One; 2016; 11(4):e0153140. PubMed ID: 27050469
[TBL] [Abstract][Full Text] [Related]
32. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW; van der Heijde DM; Smolen JS; Maini RN; Bathon JM; Emery P; Keystone E; Schiff M; Kalden JR; Wang B; Dewoody K; Weiss R; Baker D;
Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
[TBL] [Abstract][Full Text] [Related]
34. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.
van der Bijl AE; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Ten Wolde S; Han KH; van Krugten MV; Allaart CF; Breedveld FC; Dijkmans BA
Arthritis Rheum; 2007 Jul; 56(7):2129-34. PubMed ID: 17599726
[TBL] [Abstract][Full Text] [Related]
35. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
Caramaschi P; Canestrini S; Biasi D; Carletto A; Scambi C; Scarperi A; Bambara LM
Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995
[TBL] [Abstract][Full Text] [Related]
36. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
38. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis.
Wakefield RJ; Freeston JE; Hensor EM; Bryer D; Quinn MA; Emery P
Arthritis Rheum; 2007 Dec; 57(8):1564-7. PubMed ID: 18050231
[No Abstract] [Full Text] [Related]
39. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
40. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]